International Application No. PCT/EP2004/014379
International Filing Date: 14 December 2004

## **Amendments to the claims**

This listing of claims will replace all prior versions, and listings, of claims in the application:

- 1. (Original) An immunogenic composition comprising:
- (a) an immunogen comprising
- (i) IL-12, IL-23, or a subunit or component thereof; and
- (ii) a carrier; and
- (b) an adjuvant comprising one or more of cholesterol; oil-in-water emulsion; oil-in-water emulsion low dose; tocopherol; liposome; QS21; and 3D-MPL.
- 2. (Currently amended) An <u>The</u> immunogenic composition according to claim 1 in which the immunogen comprises the P35 subunit of IL-12.
- 3. (Currently amended) An <u>The</u> immunogenic composition according to claim 1 in which the immunogen comprises the P40 subunit of IL-12 or IL-23.
- 4. (Currently amended) An The immunogenic composition according to claim 2 or 3 in which the immunogen comprises at least one surface epitope of P35 or P40.
- 5. (Currently amended) An The immunogenic composition according to claim 1 in which the carrier comprises one or more of: Keyhole Limpet Haemocyanin (KLH); bovine serum albumin (BSA); tetanus toxin (TT), diphtheria toxin (DT); Domain 1 of Fragment C of TT; the translocation domain of DT; Hep B core protein; PADRE; P2; and P30.
- 6. (Currently amended) An The immunogenic composition according to any preceding claim 1 in which component (i) is coupled to the carrier by direct covalent coupling.
- 7. (Currently amended) An <u>The</u> immunogenic composition according to any of claims 1 to 5 claim 1 in which component (i) is fused to the carrier.

International Application No. PCT/EP2004/014379 International Filing Date: 14 December 2004

- 8. (Currently amended) An The immunogenic composition according to any preceding claim 1 in which the adjuvant comprises liposome, 3D-MPL and QS21.
- 9. (Currently amended) An <u>The</u> immunogenic composition according to any of claims 1 to 7 claim 1 in which the adjuvant comprises oil-in-water emulsion low dose; 3D-MPL and QS21.
- 10. (Currently amended) An The immunogenic composition according to any of claims 1 to 7 claim 1 in which the adjuvant comprises oil-in-water emulsion low dose; 3D-MPL and QS21.
- 11. (Currently amended) An <u>The</u> immunogenic composition according to any of claims 1 to 7 claim 1, in which the adjuvant comprises oil-in-water emulsion.
- 12. (Currently amended) A <u>The</u> process for the manufacture of an immunogenic composition according to <u>any of claims 1 to 11 claim 1</u> comprising mixing immunogen (a) with the adjuvant.
- 13. (Currently amended) A <u>The</u> vaccine composition comprising the immunogenic composition as described in <del>any of claims 1 to 12</del> <u>claim 1</u> in combination with a pharmaceutically acceptable excipient, adjuvant or vehicle.
- 14. (Currently amended) A process for the manufacture of a making the vaccine composition according to claim 13 comprising mixing the <u>an</u> immunogenic composition of any of claims 1 to 11 comprising:
  - (a) an immunogen comprising
  - (i) IL-12, IL-23, or a subunit or component thereof; and
  - (ii) a carrier; and
- (b) an adjuvant comprising one or more of cholesterol; oil-in-water emulsion; oil-in-water emulsion low dose; tocopherol; liposome; QS21; and 3D-MPL with a pharmaceutically acceptable excipient, adjuvant or vehicle.
- 15. (Currently amended) A <u>The</u> method of preventing or treating a disease or disorder, in particular an autoimmune-implicated disease by

International Application No. PCT/EP2004/014379 International Filing Date: 14 December 2004

administration of an immunogenic or vaccine composition according to any of claims 1 to 11 or 13 claim 1.

## 16. (Cancelled)

- 17. (Currently amended) A <u>The</u> method <del>or use</del> according to claim 15 <del>or</del> <del>16</del>, in which the <del>medicament or</del> composition is for prevention, therapy or treatment of a disease or disorder of a mammal.
- 18. (Currently amended) A <u>The</u> method <del>or use</del> according to <del>any of claims</del> 15 to 17 <u>claim 15</u>, in which the <del>medicament or</del> composition is for prevention, therapy or treatment of a disease or disorder of a human.
- 19. (Currently amended) A <u>The</u> method er use according to any of claims 15 to 18 claim 15, in which the medicament or composition is for prevention, therapy or treatment of <u>a disorder chosen from the group of</u>: multiple sclerosis; Crohn's disease; thyroiditis; er <u>and</u> rheumatoid arthritis.
- 20. (Original) A kit comprising an immunogen according to any preceding claim and an adjuvant comprising one or more of cholesterol; oil-in-water emulsion; oil-in-water emulsion low dose; tocopherol; liposome; QS21; and 3D-MPL.